Swiss biotech AC Immune announced a 30% reduction in staff alongside a strategic pipeline downsizing, preserving cash runway extension of approximately six months. The company will deprioritize at least three preclinical candidates while focusing resources on an in-house phase 2 Parkinson’s disease candidate (ACI-7104.056) and partnered Alzheimer’s disease assets with Johnson & Johnson, Takeda, and Eli Lilly. These moves aim to optimize focus amid funding challenges and market dynamics.